-
Mashup Score: 4Cardiac arrest in COVID-19 pandemic: ‘Survival is possible’ - 4 year(s) ago
Results of new studies of in- and out-of-hospital cardiac arrest underline that, despite lower survival rates during the pandemic, rates are “not zero,” and response is “not futile.”
Source: www.mdedge.comCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 3
“You’re seeing a paradigm shift right here in front of your eyes today. This could be a game changer in terms of preventing large numbers of cardiovascular events.” —Dr. Donald Lloyd-Jones
Source: www.mdedge.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
TIPS-3 Trial: A once-daily polypill reduced major cardiovascular events by 21% and when adding 75 mg of aspirin the risk reduction was increased to 31%. https://t.co/wilwrFIBlp #AHA20 #AHA2020 https://t.co/RCYVxHS3Hd
-
-
Mashup Score: 0
Results of SEARCH-AF trial show one in five cardiac surgery patients with no history of atrial fibrillation develop it within 30 days post discharge.
Source: www.mdedge.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Data from the SEARCH-AF-trial should help inform clinicians on monitoring for postoperative #AFib in patients with no history. https://t.co/JKWSrvDn9R #AHA20 #AHA2020 https://t.co/Xl9FNJKXDJ
-
-
Mashup Score: 3VTEs tied to immune checkpoint inhibitor cancer treatment - 4 year(s) ago
Retrospective analysis hints that cancer patients have an elevated risk for venous thromboembolism following treatment with an immune checkpoint inhibitor.
Source: www.mdedge.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Study: #Cardiologists raise an important alert for clinicians of the potential for #VTE following ICI treatment. https://t.co/gg4js2MsG8 #AHA20 #AHA2020 https://t.co/gVAgFiuKwj
-
-
Mashup Score: 0
Omecamtiv mecarbil safely met its primary efficacy endpoint in patients with heart failure with reduced ejection fraction in GALACTIC-HF, but with a modest effect.
Source: www.mdedge.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
#AHA20: Omecamtiv mecarbil safely produced significant improvement in #HFrEF in the GALACTIC-HF trial. via https://t.co/egLueLO56C #AHA2020 @HeartNews @jteerlinkmd @paheidenreich @WashU_cards https://t.co/AHf7AnapyN
-
-
Mashup Score: 1AHA: American Heart Association | MDedge Cardiology - 4 year(s) ago
Conference Coverage SAMSON pins most muscle pain experienced with statins on the nocebo effect Author: Steve Stiles …
Source: www.mdedge.comCategories: General Medicine News, Latest HeadlinesTweet-
RT @MDedgeCardio: Final Day of #AHA20: In case you missed it, click the link for full conference coverage. https://t.co/imrNfujUwV #AHA2020…
-
-
Mashup Score: 5
The 300-patient trial is the largest to date, used implanted loop recorders to gauge A-fib burden, and saw no price paid for safety.
Source: TCTMD.comCategories: Future of Medicine, Latest HeadlinesTweet-
EARLY-AF trial results: “The major takeaway is that for every arrhythmia outcome we studied, #ablation was significantly better than antiarrhythmic drugs.” @DrJasonAndrade #AFib #AHA2020 #EPeeps via @ShelleyWood2 @TCTMD https://t.co/i3fPIgfpKp
-
-
Mashup Score: 1VITAL-AF, mSToPS: Mixed Results in Afib Screening - 4 year(s) ago
A signal that screening by continuous ECG monitoring leads to better outcomes
Source: www.medpagetoday.comCategories: Cardiologists, Latest HeadlinesTweet-
RT @DebbeMcCall: #AFib updates from #AHA2020 https://t.co/XqtMRAa3AR https://t.co/JyiYKUI8qT
-
-
Mashup Score: 1
Neither supplement, here used as drugs, made a difference in risk for incident atrial fibrillation in the 5-year trial. And a secondary sensitivity analysis contained a cautionary signal.
Source: MedscapeCategories: Cardiology News and Journals, Latest HeadlinesTweet-
#AHA20: In the VITAL-Rhythm trial, neither marine-oil caps nor the vitamin D3 supplements made a difference in AF. https://t.co/L5o7DalPUK #AHA2020 @HeartNews https://t.co/Fw45KHmWi1
-
-
Mashup Score: 0
November 16, 2020 — The use of the more potent antiplatelet medication ticagrelor (Brilinta) was not superior to clopidogrel in the reduction of heart attacks or severe complications among people undergoing an elective percutaneous coronary intervention (PCI), according to late-breaking research presented at the 2020 American Heart Association (AHA) Scientific Sessions.
Source: DAICCategories: Cardiologists, Latest HeadlinesTweet-
Ticagrelor Not Superior to Clopidogrel in Reducing Heart Attacks During PCI https://t.co/xt5qHvOGH3 #AHA2020 #cardiology #cathlab #cardiotwitter #PCI
-
#AHA20: Out-of-hospital cardiac arrest research shows that patients with COVID-19 had rates that were better than previously reported. https://t.co/pv4w0zMl40 #AHA2020 @OscarJMitchell @BenjaminAbella @CHsu1012 https://t.co/cyj1ycWsFl